Series Editor
John M. Walker
School of Life Sciences
University of Hertfordshire
Hatfield, Hertfordshire, AL10 9AB, UK

For other titles published in this series, go to
www.springer.com/series/7651
Preface

In a rational drug discovery approach, it is necessary to identify the cause of the disease and its mechanism at the molecular level. Protein molecules that are the basic cause of the disease are identified first. Altering or modifying the protein–protein interaction could lead to therapeutic agents. The state-of-the-art methodology in drug discovery demands rational drug design, which will lower side effects and enhance therapeutic effects. Research in the pharmaceutical sciences and medicinal chemistry has taken an important new direction in the past two decades with a focus on large molecules, especially peptides and proteins, and DNA therapeutics. Protein and peptide drugs are currently the most rapidly expanding class of drugs. At present, more than 130 different proteins or peptides have been approved for clinical use. Whether it is peptide/protein-based drugs or organic molecules, the process of drug discovery involves several steps. The first is target identification and lead optimization. In the former process, molecules that bind a drug target and modulate the biological activity are identified using an in vitro assay, while in the latter potential drug molecules are optimized with respect to in vitro potency and other important parameters reflecting bioavailability and pharmacokinetic or toxicological properties. When a therapeutic target has been identified and validated, the next stage in drug discovery is to conduct high-throughput screening based on target binding or cellular assay to identify a lead compound. Once a lead compound is identified, the compound is modified chemically for higher activity and less toxicity. This involves the synthesis of a large number of analogs of the lead compound and testing them for biological activity. With several hundred protein targets available, screening thousands of compounds for biological activity and toxicity is a tedious and time-consuming process. In recent years, there has been an interest in disrupting protein–protein interactions using small molecules and peptides. With this interest in protein–protein interactions for targeting drugs, the number of drug targets will increase from hundreds to thousands. Once the drug-like molecule enters preclinical and clinical trials, it becomes an extremely expensive task to study each target. Hence, several methods have been discovered to screen compounds that may have drug-like properties. These methods involve computational, spectroscopic, analytical, and purification methods, cellular assays, and molecular biology methods. In this particular volume of *Methods in Molecular Biology*, we present 16 chapters related to drug discovery and screening. It is impossible to cover all the methods related to drug discovery in a single volume. Our intent is to give an in-depth view of some protocols that are commonly used in drug discovery laboratories. Some of these techniques may be old and some are relatively new. They include computational docking, quantitative structure–activity relationship (QSAR), peptide synthesis, labeling of peptides and proteins with fluorescent labels, DNA-microarray, zebrafish model for drug screening, and other analytical screening and biological assays that are routinely used during the drug discovery process. With the availability of three-dimensional structures of protein/DNA target molecules, computational methods have played a key role in designing and screening thousands of compounds as possible candidates for druggable molecules. Hence, we have covered computational methods in
detail. Cellular and whole body imaging using fluorescently labeled molecules have gained popularity compared to procedures using radioactively labeled compounds. The method of fluorescent labeling of peptides and proteins is covered in detail in one chapter. Overall, this volume will serve as a laboratory reference for pharmaceutical chemists, medicinal chemists, and pharmacologists as well as for molecular biologists.

I would like to thank my wife, Latha Nagarajarao, for helping me to edit the chapters. Thanks to Dr. John Walker, chief editor of the series, for his advice and to all the authors who contributed to this series for their valuable time and sharing their detailed knowledge.

Monroe, LA

Seetharama D. Satyanarayanajois
# Contents

*Preface* ............................................................ v  
*Contributors* ............................................................ ix  

1 Virtual Screening for Lead Discovery .......................... 1  
*Tat T. Tang and Garland R. Marshall*  

2 Computer-Aided Drug Discovery and Development .......... 23  
*Shuxing Zhang*  

3 Using Active Site Mapping and Receptor-Based Pharmacophore Tools: Prelude to Docking and De Novo/Fragment-Based Ligand Design ................................................... 39  
*Ashutosh Tripathi, J. Andrew Surface, and Glen E. Kellogg*  

4 Methods for Evaluation of Structural and Biological Properties of Antiinvasive Natural Products .......................... 55  
*Mudit Mudit, Mohammad Khanfar, Girish V. Shah, and Khalid A. El Sayed*  

5 Solid-Phase Peptide Synthesis Using Microwave Irradiation . 73  
*Justin K. Murray, Jennifer Aral, and Les P. Miranda*  

6 Fluorescent and Lanthanide Labeling for Ligand Screens, Assays, and Imaging ............................................... 89  
*Jatinder S. Josan, Channa R. De Silva, Byunghee Yoo, Ronald M. Lynch, Mark D. Pagel, Josef Vagner, and Victor J. Hruby*  

7 DNA-Directed Assembly Microarray for Protein and Small Molecule Inhibitor Screening .................................. 127  
*Ng Jin Kiat, Fritz Simeon, Too Heng Phon, and Parayil Kumaran Ajikumar*  

8 Selection of Peptide Ligands for Human Placental Transcytosis Systems Using In Vitro Phage Display ....................... 141  
*Saleem Basha, Sruhti Vaidyanathan, and Giovanni M. Pauletti*  

9 Optimization of the Tetrazolium Dye (MTT) Colorimetric Assay for Cellular Growth and Viability .......................... 157  
*Paul W. Sylvester*  

10 Imaging NF-κB Signaling in Mice for Screening Anticancer Drugs .......... 169  
*Delira Robbins and Yunfeng Zhao*  

11 Evaluation of Anticancer Agents Using Flow Cytometry Analysis of Cancer Stem Cells .................................. 179  
*Vineet Gupta, Qian-Jin Zhang, and Yong-Yu Liu*  

12 Chemical Screening with Zebrafish Embryos .......................... 193  
*Hanbing Zhong and Shuo Lin*
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>iTRAQ™ Labeling Coupled with LC-MALDI Mass Spectrometry for Monitoring Temporal Response of Colorectal Cancer Cells to Butyrate Treatment</td>
<td>207</td>
</tr>
<tr>
<td></td>
<td><em>Hwee Tong Tan, Teck Kwang Lim, Maxey C.M. Chung, and Qingsong Lin</em></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Heterotypic Cell Adhesion Assay for the Study of Cell Adhesion Inhibition</td>
<td>225</td>
</tr>
<tr>
<td></td>
<td><em>Seetharama D. Satyanarayanajois, Sharon Ronald, and Jining Liu</em></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Evaluation of Antibacterial Activity of Proteins and Peptides Using a Specific Animal Model for Wound Healing</td>
<td>245</td>
</tr>
<tr>
<td></td>
<td><em>Ramar Perumal Samy, Maung Maung Thwin, Vincent T.K. Chow, Ho Bow, and Ponnampalam Gopalakrishnakone</em></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>In Vitro Immunogenicity Risk Assessment of Therapeutic Proteins in Preclinical Setting</td>
<td>267</td>
</tr>
<tr>
<td></td>
<td><em>Puneet Gaitonde and Sathy V. Balu-Iyer</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Index</strong></td>
<td>281</td>
</tr>
</tbody>
</table>
Contributors

Parayil Kumaran Ajikumar • Singapore-Massachusetts Institute of Technology Alliance (SMA), National University of Singapore, Singapore
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA

Jennifer Aral • Peptide Research & Discovery, Amgen, Thousand Oaks, CA, USA

Sathy V. Balu-Iyer • Department of Pharmaceutical Sciences, SUNY – University, Buffalo, Amherst, NY, USA

Saleem Basha • James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA

Ho Bow • Department of Microbiology, National University of Singapore, Singapore

Vincent T.K. Chow • Department of Microbiology, National University of Singapore, Singapore

Maxey C.M. Chung • Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore

Channa R. De Silva • Department of Chemistry, University of Arizona, Tucson, AZ, USA

Khalid A. El Sayed • Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA, USA

Puneet Gaïtone • Department of Pharmaceutical Sciences, SUNY – University, Buffalo, Amherst, NY, USA

Ponnampalam Gopalakrishnakone • Venom and Toxin Research Program, Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Vineet Gupta • Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, LA, USA

Victor J. Hruby • Department of Chemistry, University of Arizona, Tucson, AZ, USA

Jatinder S. Josan • Department of Chemistry, University of Arizona, Tucson, AZ, USA

Glen E. Kellogg • Department of Medicinal Chemistry & Institute for Structural Biology and Drug Discovery, Virginia Commonwealth University, Richmond, VA, USA

Mohammad Khanfar • Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA, USA

Ng Jin Kiat • Singapore-Massachusetts Institute of Technology Alliance (SMA), National University of Singapore, Singapore
TECK KWANG LIM  •  Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore
QINGSONG LIN  •  Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore
SHUO LIN  •  Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA, USA
JINING LIU  •  Estee Lauder Companies Innovation Institute (China), Shanghai, China
YONG-YU LIU  •  Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, LA, USA
RONALD M. LYNCH  •  Bio5 Institute, University of Arizona, Tucson, AZ, USA
GARLAND R. MARSHALL  •  Center for Computational Biology, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA
LES P. MIRANDA  •  Peptide Research and Discovery, Amgen, Thousand Oaks, CA, USA
JUSTIN K. MURRAY  •  Peptide Research & Discovery, Amgen, Thousand Oaks, CA, USA
MUDIT MUDIT  •  Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA, USA; Department of Pharmaceutical Sciences, D’Youville College, School of Pharmacy, Buffalo, NY, USA
GIOVANNI M. PAULETTI  •  James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA
MARK D. PAGEL  •  Department of Chemistry, University of Arizona, Tucson, AZ, USA
TOO HENG PHON  •  Singapore-Massachusetts Institute of Technology Alliance (SMA), National University of Singapore, Singapore
DELIRA ROBBINS  •  Department of Pharmacology, Toxicology, & Neuroscience, Louisiana State University Health Sciences Center in Shreveport, Shreveport, LA, USA
SHARON RONALD  •  Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA, USA
RAMAR PERUMAL SAMY  •  Venom and Toxin Research Program, Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
SEETHARAMA D. SATYANARAYANAJOIS  •  Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA, USA
GIRISH V. SHAH  •  Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA, USA
FRITZ SIMEON  •  Singapore-Massachusetts Institute of Technology Alliance (SMA), National University of Singapore, Singapore
J. ANDREW SURFACE  •  Department of Medicinal Chemistry & Institute for Structural Biology and Drug Discovery, Virginia Commonwealth University, Richmond, VA, USA
PAUL W. SYLVESTER  •  Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA, USA
Contributors

Hwee Tong Tan • Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Yat T. Tang • Center for Computational Biology, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA

Maung Maung Thwin • Venom and Toxin Research Program, Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Ashutosh Tripathi • Department of Medicinal Chemistry & Institute for Structural Biology and Drug Discovery, Virginia Commonwealth University, Richmond, VA, USA

Josef Vagner • Bio5 Institute, University of Arizona, Tucson, AZ, USA

Shruthi Vaidhyanathan • James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA

Byunghee Yoo • Department of Chemistry, University of Arizona, Tucson, AZ, USA

Qian-Jin Zhang • Department of Biology, Xavier University of Louisiana, New Orleans, LA, USA

Shuxing Zhang • Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, TX, USA

Yunfeng Zhao • Department of Pharmacology, Toxicology, & Neuroscience, Louisiana State University Health Sciences Center in Shreveport, Shreveport, LA, USA

Hanbing Zhong • Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Shenzhen Graduate School of Peking University, Shenzhen University Town Shenzhen, China